Molecular aptamers for drug delivery

Trends in Biotechnology

Volumn 29, Issue 12, 2011, Pages 634-640

  Tan, Weihong ^a,b   Wang, Hui ^b   Chen, Yan ^a,b,c   Zhang, Xiaobing ^a   Zhu, Haizhen ^a   Yang, Chaoyong ^c   Yang, Ronghua ^a   Liu, Chen ^b  

^a HUNAN UNIVERSITY   (China)

^b UNIVERSITY OF FLORIDA   (United States)

^c XIAMEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVE TARGETING; APTAMERS; CHEMICAL SYNTHESIS; GOLD NANOROD; HIGH AFFINITY; MOLECULAR PROBES; RECENT PROGRESS;

CARBON NANOTUBES; CHEMICAL MODIFICATION; DRUG DELIVERY; NANORODS; SYNTHESIS (CHEMICAL); TISSUE;

DISEASES;

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; APTAMER; AS 1411; CISPLATIN; CYTOTOXIC AGENT; DNA APTAMER; DOXORUBICIN; DOXORUBICIN ANTIBODY CONJUGATE; DOXORUBICIN APTAMER CONJUGATE; GOLD NANOPARTICLE; LIPOSOME; MACROGOL; NANOMATERIAL; NANOROD; PEGAPTANIB; PHOTOSENSITIZING AGENT; POLYACRYLAMIDE; PROSTATE SPECIFIC ANTIGEN; RNA APTAMER; SILVER NANOPARTICLE; SMALL INTERFERING RNA; TDO 5; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; BINDING AFFINITY; BREAST CANCER; BURKITT LYMPHOMA; CELL MEMBRANE; CELL SELEX TECHNIQUE; COMBINATORIAL CHEMISTRY; COMPUTER ASSISTED TOMOGRAPHY; CROSS LINKING; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; ENCAPSULATION; EXUDATIVE MACULAR DEGENERATION; HUMAN; HYDROGEL; INTERNALIZATION; LIVER CELL CARCINOMA; MICELLE; MOLECULAR IMAGING; MOLECULAR RECOGNITION; MOLECULARLY TARGETED THERAPY; NANOTECHNOLOGY; NONHUMAN; PERSONALIZED MEDICINE; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROSTATE CANCER; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; RNA INTERFERENCE; SIGNAL TRANSDUCTION; VIRUS INHIBITION;

APTAMERS, NUCLEOTIDE; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS;

EID: 81155150134     PISSN: 01677799     EISSN: 18793096     Source Type: Journal    
DOI: 10.1016/j.tibtech.2011.06.009     Document Type: Review

References (69)

1. Cerchia L., de Franciscis V. Targeting cancer cells with nucleic acid aptamers. Trends Biotechnol. 2010, 28:517-525.
2. Keefe A.D., et al. Aptamers as therapeutics. Nat. Rev. Drug Discov. 2010, 9:537-550.
3. Osborne S.E., et al. Aptamers as therapeutic and diagnostic reagents: problems and prospects. Curr. Opin. Chem. Biol. 1997, 1:5-9.
4. Famulok M., et al. Functional aptamers and aptazymes in biotechnology, diagnostics, and therapy. Chem. Rev. 2007, 107:3715-3743.
5. Navani N.K., Li Y.F. Nucleic acid aptamers and enzymes as sensors. Curr. Opin. Chem. Biol. 2006, 10:272-281.
6. Jiang Y.X., et al. Specific aptamer-protein interaction studied by atomic force microscopy. Anal. Chem. 2003, 75:2112-2116.
7. Griffin L.C., et al. The discovery and characterization of a novel nucleotide-based thrombin inhibitor. Gene 1993, 137:25-31.
8. Ferreira C.S., et al. DNA aptamers against the MUC1 tumour marker: design of aptamer-antibody sandwich ELISA for the early diagnosis of epithelial tumours. Anal. Bioanal. Chem. 2008, 390:1039-1050.
9. Balogh Z., et al. Selection and versatile application of virus-specific aptamers. FASEB J. 2010, 24:4187-4195.
10. Shangguan D., et al. Aptamers evolved from live cells as effective molecular probes for cancer study. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:11838-11843.
11. Li J.W.J., et al. Molecular aptamer beacons for real-time protein recognition. Biochem. Biophys. Res. Commun. 2002, 292:31-40.
12. Gutsaeva D.R., et al. Inhibition of cell adhesion by anti-P-selectin aptamer: a new potential therapeutic agent for sickle cell disease. Blood 2011, 117:727-735.
13. Lu C., et al. Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models. Cancer Biol. Ther. 2010, 9:176-182.
14. Wu Y.R., et al. DNA aptamer-micelle as an efficient detection/delivery vehicle toward cancer cells. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:5-10.
15. Huang Y.F., et al. Selective photothermal therapy for mixed cancer cells using aptamer-conjugated nanorods. Langmuir 2008, 24:11860-11865.
16. Chu T.C., et al. Aptamer mediated siRNA delivery. Nucleic Acids Res. 2006, 34:e73.
17. Davis K.A., et al. Staining of cell surface human CD4 with 2'-F-pyrimidine-containing RNA aptamers for flow cytometry. Nucleic Acids Res. 1998, 26:3915-3924.
18. Conrad R., Ellington A.D. Detecting immobilized protein kinase C isozymes with RNA aptamers. Anal. Biochem. 1996, 242:261-265.
19. Murphy M.B., et al. An improved method for the in vitro evolution of aptamers and applications in protein detection and purification. Nucleic Acids Res. 2003, 31:e110.
20. Floege J., et al. Novel approach to specific growth factor inhibition in vivo-antagonism of platelet-derived growth factor in glomerulonephritis by aptamers. Am. J. Pathol. 1999, 154:169-179.
21. Ostendorf T., et al. The effects of platelet-derived growth factor antagonism in experimental glomerulonephritis are independent of the transforming growth factor-beta system. J. Am. Soc. Nephrol. 2002, 13:658-667.
22. White R.R., et al. Inhibition of rat corneal angiogenesis by a nuclease-resistant RNA aptamer specific for angiopoietin-2. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:5028-5033.
23. Mayer G., et al. Fluorescence-activated cell sorting for aptamer SELEX with cell mixtures. Nat. Protoc. 2010, 5:1993-2004.
24. Raddatz M.S., et al. Enrichment of cell-targeting and population-specific aptamers by fluorescence-activated cell sorting. Angew. Chem. Int. Ed. Engl. 2008, 47:5190-5193.
25. Sefah K., et al. Molecular recognition of acute myeloid leukemia using aptamers. Leukemia 2009, 23:235-244.
26. Zhao Z.L., et al. Recognition of subtype non-small cell lung cancer by DNA aptamers selected from living cells. Analyst 2009, 134:1808-1814.
27. Chen H.W., et al. Molecular recognition of small-cell lung cancer cells using aptamers. Chem. Med. Chem. 2008, 3:991-1001.
28. Tang Z.W., et al. Generating aptamers for recognition of virus-infected cells. Clin. Chem. 2009, 55:813-822.
29. Guo K.T., et al. A new technique for the isolation and surface immobilization of mesenchymal stem cells from whole bone marrow using high-specific DNA aptamers. Stem Cells 2006, 24:2220-2231.
30. Hoffmann J., et al. Immobilized DNA aptamers used as potent attractors for porcine endothelial precursor cells. J. Biomed. Mater. Res. A 2008, 84A:614-621.
31. Hamula C.L.A., et al. Selection of aptamers against live bacterial cells. Anal. Chem. 2008, 80:7812-7819.
32. Ulrich H., et al. In vitro selection of RNA aptamers that bind to cell adhesion receptors of Trypanosoma cruzi and inhibit cell invasion. J. Biol. Chem. 2002, 277:20756-20762.
33. Kuliczkowski W., et al. Aptamers: the emerging class of future anticoagulation for vascular disease. Expert Rev. Cardiovasc. Ther. 2010, 8:503-507.
34. Joeng C.B., et al. ssDNA aptamers that recognize diclofenac and 2-anilinophenylacetic acid. Bioorg. Med. Chem. 2009, 17:5380-5387.
35. Nonaka Y., et al. Screening and improvement of an anti-VEGF DNA aptamer. Molecules 2010, 15:215-225.
36. Choi J.H., et al. DNA aptamer-passivated nanocrystal synthesis: a facile approach for nanoparticle-based cancer cell growth inhibition. Small 2009, 5:672-675.
37. Dollins C.M., et al. Aptamers in immunotherapy. Hum. Gene Ther. 2008, 19:443-450.
38. Bates P.J., et al. Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer. Exp. Mol. Path. 2009, 86:151-164.
39. Ireson C.R, Kelland L.R. Discovery and development of anticancer aptamers. Mol. Cancer Ther. 2006, 5:2957-2962.
40. Lou X.H., et al. Micromagnetic selection of aptamers in microfluidic channels. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:2989-2994.
41. Sefah K., et al. Development of DNA aptamers using Cell-SELEX. Nat. Protoc. 2010, 5:1169-1185.
42. Cao Z.H., et al. Reversible cell-specific drug delivery with aptamer-functionalized liposomes. Angew. Chem. Int. Ed. 2009, 48:6494-6498.
43. Shangguan D.H., et al. Identification of liver cancer-specific aptamers using whole live cells. Anal. Chem. 2008, 80:721-728.
44. Tang Z.W., et al. Selection of aptamers for molecular recognition and characterization of cancer cells. Anal. Chem. 2007, 79:4900-4907.
45. Dyke C.K., et al. First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology-a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity. Circulation 2006, 114:2490-2497.
46. Huang Y.F., et al. Cancer cell targeting using multiple aptamers conjugated on nanorods. Anal. Chem. 2008, 80:567-572.
47. Kim D., et al. A drug-loaded aptamer-gold nanoparticle bioconjugate for combined CT imaging and therapy of prostate cancer. ACS Nano 2010, 4:3689-3696.
48. Farokhzad O.C., et al. Nanopartide-aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res. 2004, 64:7668-7672.
49. Li L., et al. Triggered content release from optimized stealth thermosensitive liposomes using mild hyperthermia. J. Control. Release 2010, 143:274-279.
50. Yang H., et al. Comparative-studies of in-vitro and in-vivo function of 3 different shaped bioartificial pancreases made of agarose hydrogel. Biomaterials 1994, 15:113-120.
51. Soontornworajit B., et al. Aptamer-functionalized in situ injectable hydrogel for controlled protein release. Biomacromolecules 2010, 11:2724-2730.
52. Liu H., et al. DNA-based micelles: synthesis, micellar properties and size-dependent cell permeability. Chemistry 2010, 16:3791-3797.
53. Zhu Z., et al. Regulation of singlet oxygen generation using single-walled carbon nanotubes. J. Am. Chem. Soc. 2008, 130:10856-10857.
54. Kang H.Z., et al. A liposome-based nanostructure for aptamer directed delivery. Chem. Commun. 2010, 46:249-251.
55. Willis M.C., et al. Liposome anchored vascular endothelial growth factor aptamers. Bioconjug. Chem. 1998, 9:573-582.
56. Huang Y.F., et al. Molecular assembly of an aptamer-drug conjugate for targeted drug delivery to tumor cells. Chem. Biochem. 2009, 10:862-868.
57. Inoh K., et al. Doxorubicin-conjugated anti-midkine monoclonal antibody as a potential anti-tumor drug. Jpn. J. Clin. Oncol. 2006, 36:207-211.
58. Elbashir S.M., et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001, 411:494-498.
59. Zhou J., et al. Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy. Mol. Ther. 2008, 16:1481-1489.
60. Dassie J.P., et al. Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat. Biotechnol. 2009, 27:839-849.
61. McNamara J.O., et al. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat. Biotechnol. 2006, 24:1005-1015.
62. Farokhzad O.C., et al. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:6315-6320.
63. Li N., et al. Directed evolution of gold nanoparticle delivery to cells. Chem. Commun. (Camb.) 2010, 46:392-394.
64. Ferreira C.S.M., et al. Phototoxic aptamers selectively enter and kill epithelial cancer cells. Nucleic Acids Res. 2009, 37:866-876.
65. Da Pieve C., et al. Anti-MUC1 aptamers: radiolabelling with Tc-99m and biodistribution in MCF-7 tumour-bearing mice. Nucl. Med. Biol. 2009, 36:703-710.
66. McNamara J.O., et al. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat. Biotechnol. 2006, 24:1005-1015.
67. Chu T.C., et al. Aptamer: toxin conjugates that specifically target prostate tumor cells. Cancer Res. 2006, 66:5989-5992.
68. Bagalkot V., et al. Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on Bi-fluorescence resonance energy transfer. Nano Lett. 2007, 7:3065-3070.
69. Sefah K., et al. Development of DNA aptamers using cell-SELEX. Nat. Protoc. 2010, 5:1169-1185.